Cardiology

Study compares anticoagulants for antiphospholipid syndrome

(HealthDay)—In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.

page 1 from 23